TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02816567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMBA - cisatracurium
Study: NCT00535951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT05369247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity Interval Training
Description: HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., \> 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity Interval Training
Description: HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., \> 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).
Study: NCT02816567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo - isotonic saline serum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sufentanil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Study: NCT05369247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training
Description: The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training
Description: The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).
Study: NCT00620022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study: NCT02816567

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laparoscopic surgery
Study: NCT00620022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study: NCT02457520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
Study: NCT00715702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 100 mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 100 mg oral single dose
Study: NCT00667862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study: NCT00822497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-Based Imagery (MBI)
Description: MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Alternate Engagement (MAE)
Description: MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
Study: NCT00941837

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil, Palm Olein Oil, Coconut Oil
Description: Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil, Palm Olein Oil, Coconut Oil
Description: Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil, Palm Olein Oil, Coconut Oil
Description: Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
Study: NCT02202850

Intervention type: DRUG
Intervention: etanercept
Description: etanercept 1 x 50 mg/week or 2 x 25mg/week

Intervention type: DRUG
Intervention: etanercept
Description: etanercept 1 x 50 mg/week or 2 x 25mg/week
Study: NCT04832399

Intervention type: DRUG
Intervention: Natalizumab
Description: As described in the treatment arm.
Study: NCT02841800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 'Intra-luminal radiofrequency ablation (Habib EndoHPB)
Description: endobiliary radiofrequency ablation device
Study: NCT01878825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral™
Description: 1 dose administered intramuscularly in deltoid region of non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral™
Description: 1 dose administered intramuscularly in deltoid region of non-dominant arm.
Study: NCT01646788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMB Paclitaxel Drug Ejecting Balloon
Description: NMB's PTA Balloon catheter with drug
Study: NCT01470482

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No use of tourniquet
Description: Tourniquet is not applied i 25 pts

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: Use of tourniquet
Study: NCT04470180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Teach to Goal
Description: Participants will complete inhaler education on a tablet device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Instruction
Description: Participants will be read out loud instruction on how to use their inhaler.
Study: NCT02183753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wood smoke

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clean air
Study: NCT01287182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ateronon
Description: Ateronon daily for 3 months
Study: NCT00362973

Intervention type: RADIATION
Intervention: fludeoxyglucose F 18
Study: NCT04215757

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: peripheral nerve block
Description: peripheral nerve blocks with low dose lignocaine in acute radiculopathy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral nerve block
Description: peripheral nerve blocks with low dose lignocaine in acute radiculopathy
Study: NCT05242796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency magnetic therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency magnetic therapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low frequency magnetic therapy
Study: NCT01495312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish
Description: SLT (single session; 180 to 360 degrees of angle will be treated)
Study: NCT02931708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm functional electrical stimulation
Description: Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
Study: NCT00317278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage therapy
Description: massage therapy to stable preterm infants
Study: NCT00544934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230
Description: 125, 250 0r 375 mg bid for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230
Description: 125, 250 0r 375 mg bid for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230
Description: 125, 250 0r 375 mg bid for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No drug administered
Study: NCT02544555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intentional intraluminal approach
Description: Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intentional subintimal approach
Description: Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
Study: NCT00749333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8566
Description: solution. Specific dose will be selected by the safety review committee

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single 10ml oral solution.
Study: NCT00923429

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stay-active care
Description: No other treatment than the stay-active care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stay-active care+stretching
Description: Stay-active care and muscle stretching at home and during physiotherapist appointments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stay-active+stretching+manual therapy
Description: Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stay-active+stretching+manual therapy+steroid injections
Description: Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
Study: NCT03275909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy
Description: The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
Study: NCT01784835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
Study: NCT01180803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse oxygen supplementation devices
Description: oxygen therapy delivered by systems using oxygen-saving valves
Study: NCT00317278

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham (placebo) provided to the control group
Study: NCT01237522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: A single dose study with one tablet of metformin 500 mg, time frame 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: A single dose study with one tablet of metformin 500 mg, time frame 24 hours
Study: NCT03929822

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-Enhanced Spectral Mammography
Description: A standard dose of contrast material for other contrast mammography examinations and for body CT scanning, 1.5 ml/kg of Iohexol350 will be injected intravenously (IV) using a power injection (3-4 ml/s) with a maximum does of 150 ml. The IV injection is performed while the patient is in a sitting position. The mammogram will be performed in a standing position.
Study: NCT01361048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral metronidazole
Description: 2 gm oral once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neo penotran forte
Description: neo penotran forte intravaginal twice a day for 7 days
Study: NCT01514162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trifecta valve
Description: surgical replacement of aortic valve
Study: NCT01180803

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous oxygen
Description: oxygen therapy delivered by continuous liquid oxygen devices
Study: NCT01225666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
Study: NCT01361048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neo penotran forte once a day
Description: neo penotran forte intravaginally once a day for 7 days
Study: NCT00538421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Infusion intravenously (IV) 0-10 mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 0,7-1,5 MAC
Study: NCT02038608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Study: NCT03803800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic, progressive endurance training
Description: Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Classic, progressive endurance training
Description: Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodized exercise training
Description: Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Periodized exercise training
Description: Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Description: Some subjects will receive the ergogenic supplement beta-alanine.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Description: Some subjects will receive the ergogenic supplement beta-alanine.
Study: NCT03503422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real transcranial direct current stimulation + therapeutic exercises for back pain
Description: Real transcranial direct current stimulation associated with therapeutic exercises for back pain~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation + therapeutic exercises for back pain
Description: Sham transcranial direct current stimulation associated with therapeutic exercises for back pain.~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion). Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
Study: NCT00885456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT program
Description: 12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
Study: NCT01225666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
Study: NCT01089660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.3 mL, Intramuscular (IM)
Study: NCT02012153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Study: NCT00720265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR4
Description: oral
Study: NCT03699020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Empirically based behavioral intervention that encourages acceptance of circumstances with commitment and behavioral change strategies to improve psychological flexibility.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic Pain Education
Description: Education materials about living with chronic pain developed by Weill Cornell Universitys Translational Research Institute for Pain in Later Life
Study: NCT01988909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396
Description: Paromomycin + Gentamicin Topical Cream
Study: NCT05956366

Intervention type: BEHAVIORAL
Intervention: Family-based treatment
Description: Open-end family therapy ad modum The Maudsley model

Intervention type: BEHAVIORAL
Intervention: Family-based treatment
Description: Open-end family therapy ad modum The Maudsley model

Intervention type: BEHAVIORAL
Intervention: Family-based treatment
Description: Open-end family therapy ad modum The Maudsley model
Study: NCT04385771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vv-ECMO + cytokine adsorption (Cytosorb adsorber)
Description: in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)

Intervention type: DEVICE
Group type: OTHER
Intervention: vv-ECMO only (no cytokine adsorption)
Description: COVID-19-diseased treated with vv-ECMO
Study: NCT01089660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular (IM)
Study: NCT02601794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based Mindfulness Training
Description: A commercially available mindfulness training app delivered to smartphone or tablet.
Study: NCT03677622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven to near maximal stroke volume of the heart
Description: Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voluven to near maximal stroke volume of the heart
Description: Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
Study: NCT02495545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSFD and elevation of MAP
Description: Lumbar drain placement with CSFD with elevation of MAP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of MAP
Description: Lumbar drain placement without CSFD and with maintenance of MAP
Study: NCT00940810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Disc Decompression/Nucleoplasty
Description: Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.~Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Care (physiotherapy)
Description: Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.~Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires.